Fractyl Health (GUTS) EBIT Margin (2023 - 2024)
Fractyl Health (GUTS) recorded quarterly EBIT Margin of 840333.33% in Q4 2024, down 394.44% on a QoQ basis from 169957.14% in Q3 2024, and down 65489048.0% YoY from N/an in Q1 2024.
Powered by 
Analysis
Fractyl Health (GUTS) EBIT Margin (2023 - 2024) Analysis & Trends
Fractyl Health (GUTS) has reported EBIT Margin for 2 consecutive years, with 840333.33% the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, EBIT Margin fell 65489048.0% year-over-year to 840333.33%; the trailing twelve-month figure through Dec 2024 stood at 100570.97% (down 5820763.0% YoY), and the FY2024 full-year result was 100570.97%, down 5820763.0% from the prior year.
- EBIT Margin was 840333.33% for Q4 2024 at Fractyl Health, down from 169957.14% in the prior quarter.
- The five-year high for EBIT Margin was 16493.06% in Q2 2023, with the low at 840333.33% in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.08 Bn | 174.48 Bn | 7.27 Bn | 13.44% |
| 2 | Intuitive Surgical | 127.86 Bn | 122.64 Bn | 1.96 Bn | 33.60% |
| 3 | Medtronic | 117.15 Bn | 108.33 Bn | 6.34 Bn | 18.08% |
| 4 | Stryker | 103.82 Bn | 100.34 Bn | 4.50 Bn | 25.18% |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 21.65% |
| 6 | Edwards Lifesciences | 49.76 Bn | 45.51 Bn | 1.35 Bn | 29.48% |
| 7 | Alcon | 32.95 Bn | 31.49 Bn | 1.68 Bn | 0.40% |
| 8 | Dexcom | 32.22 Bn | 30.27 Bn | 830.00 Mn | 24.33% |
| 9 | Steris | 20.71 Bn | 20.23 Bn | 684.20 Mn | 19.15% |
| 10 | Fractyl Health | 102.41 Mn | 102.41 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -840,333.33% |
| Sep 30, 2024 | -169,957.14% |
| Jun 30, 2024 | -53,453.49% |
| Mar 31, 2024 | -65,278.79% |
| Dec 31, 2023 | -185,442.86% |
| Sep 30, 2023 | -38,536.11% |
| Jun 30, 2023 | -16,493.06% |
| Mar 31, 2023 | -242,140.00% |